Drug Profile

Research programme: oligonucleotides - Eli Lilly and Company

Latest Information Update: 26 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Dec 2022 ProQR Therapeutics and Eli Lilly and company expands their licensing and research collaboration agreement for Axiomer® platform technology with focused on the discovery, development and commercialization of new genetic medicines
27 May 2022 Preclinical trials in Liver disorders in USA (unspecified route) (ProQR Therapeutics pipeline, May 2022)
27 May 2022 Preclinical trials in Neurological disorders in USA (unspecified route) (ProQR Therapeutics pipeline, May 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com